June

June 17, 2019

Solving a century-old puzzle as to how Sesame oil functions as a pain reliever: Mechanistic insights into how Sesame oil-derived compounds function as pain medications: A pharmaceutical mixture encompassing Sesamin and Sesamol (SAS), derived from Sesame seed or oil,  increases the expression of PD-L1, decreases the expression of Cox-2, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 17/June/2019, 12.58 pm

Introduction:What they say: A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain […]
June 17, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, p12DOC1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 17/June/2019, 6.14 am

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem […]
June 17, 2019

Regenerative therapy for improving cognitive deficits in aged individuals: Chitosan, isolated from Shrimps and others, decreases vascular cell adhesion molecule 1 (VCAM 1), inhibits microglia activity, increases hippocampal neural precursor activity, ameliorates cognition, & attenuates age-related neurodegeneration, through up regulation of its target genes, 17/June/2019, 6.05 am

Introduction: What they say A study from the Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA, VA Palo Alto Health […]
June 17, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SMARCA4, KIBRA, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 17/June/2019, 5.48 am

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]